The RACE to Develop New Targeted Therapies for Children With CNS Tumors

Clin Pharmacol Ther. 2020 Sep;108(3):434-436. doi: 10.1002/cpt.1937. Epub 2020 Jul 7.

Authors

Elimika Pfuma Fletcher¹, Gilbert J Burckart¹, Giles W Robinson², Gregory H Reaman³, Clinton F Stewart⁴

Affiliations

¹ Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
² Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
³ Oncology Center for Excellence, US Food and Drug Administration, Silver Spring, Maryland, USA.
⁴ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

PMID: 32638364
DOI: 10.1002/cpt.1937

No abstract available

MeSH terms

Adolescent
Age Factors
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Central Nervous System Neoplasms / drug therapy*
Central Nervous System Neoplasms / genetics
Central Nervous System Neoplasms / metabolism
Child
Child, Preschool
Drug Approval
Humans
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Precision Medicine
Prognosis
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents
Biomarkers, Tumor